Dynavax(DVAX) - 2024 Q2 - Quarterly Results

DYNAVAX Exhibit 99.1 Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates • Achieved record quarterly HEPLISAV-B® net product revenue of $70.2 million, growing 24% year-overyear • Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million • Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025 • Conference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, CA – August 6, 2024 – Dynavax Techn ...